Latest News and Press Releases
Want to stay updated on the latest news?
-
Stockholm, 31 januari 2019. PledPharma AB (publ) meddelar att abstraktet med de positiva resultaten från Aladotes® Fas Ib/IIa proof of principle-studie har utvalts för muntlig presentation på den...
-
Stockholm, January 31, 2019. PledPharma AB (publ) announces that the abstract on the positive results from the Aladote®’s Phase Ib/IIa proof of principle-study has been selected for an oral...
-
Stockholm, 17 januari 2019. PledPharma AB (publ) meddelar att bolagets globala fas III-program, POLAR, för PledOx® har accepterats för poster-presentation på den globala konferensen Gastrointestinal...
-
Stockholm, January 17, 2019. PledPharma AB (publ) announces that the company’s global phase III program, POLAR, has been accepted for a poster presentation during the Gastrointestinal (GI) Cancers...
-
Stockholm, 10 januari 2019. PledPharma AB (publ) och Solasia Pharma K.K. meddelar att den första patienten i Japan har inkluderats till det globala fas III‑programmet för läkemedelskandidaten PledOx®....
-
Stockholm, January 10, 2019. PledPharma AB (publ) and Solasia Pharma K.K. announces that the first patient has been included in the global Phase III program for the drug candidate PledOx® in Japan....
-
Stockholm, 24 december 2018. PledPharma AB (publ) meddelar att bolaget har lämnat in en ansökan till amerikanska läkemedelsmyndigheten FDA om särläkemedelsstatus (ODD, Orphan Drug Designation) för...
-
Stockholm, December 24, 2018. PledPharma AB (publ) announces that the company has filed an application for an Orphan Drug Designation (ODD) to the US FDA for the drug candidate Aladote®, developed to...
-
Stockholm, 13 december 2018. PledPharma AB (publ) meddelar att bolagets Aladote® fas Ib/IIa studieresultat har accepterats för presentation på den globala toxikologikonferensen ”58th Annual Meeting of...
-
Stockholm, December 13, 2018. PledPharma AB (publ) announces that the company's Aladote® Phase Ib/IIa study results has been accepted for a poster presentation during the “58th Annual Meeting of the...